Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Receivables: 2018-2025

Historic Change in Receivables for Aclaris Therapeutics (ACRS) over the last 6 years, with Jun 2025 value amounting to -$56,000.

  • Aclaris Therapeutics' Change in Receivables fell 16.67% to -$56,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$131,000, marking a year-over-year decrease of 23.58%. This contributed to the annual value of $20,000 for FY2024, which is 110.75% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Change in Receivables stood at -$56,000 for Q2 2025, which was up 17.65% from -$68,000 recorded in Q1 2025.
  • In the past 5 years, Aclaris Therapeutics' Change in Receivables ranged from a high of $202,000 in Q1 2023 and a low of -$255,000 during Q2 2023.
  • Over the past 3 years, Aclaris Therapeutics' median Change in Receivables value was -$48,000 (recorded in 2024), while the average stood at -$29,000.
  • Within the past 5 years, the most significant YoY rise in Aclaris Therapeutics' Change in Receivables was 1,920.00% (2023), while the steepest drop was 6,475.00% (2023).
  • Aclaris Therapeutics' Change in Receivables (Quarterly) stood at -$188,000 in 2021, then surged by 39.89% to -$113,000 in 2022, then soared by 57.52% to -$48,000 in 2023, then soared by 47.92% to -$25,000 in 2024, then fell by 16.67% to -$56,000 in 2025.
  • Its Change in Receivables was -$56,000 in Q2 2025, compared to -$68,000 in Q1 2025 and -$25,000 in Q4 2024.